Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting

Merav Cohen, Moshe Elkahets, Michal Perlmutter, Angel Porgador, Elena Voronov, Ron N. Apte and Rachel G. Lichtenstein

*J Immunol* 2010; 185:5869-5878; Prepublished online 18 October 2010;
doi: 10.4049/jimmunol.1001635
http://www.jimmunol.org/content/185/10/5869

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2010/10/19/jimmunol.1001635.DC1

**References**
This article cites 50 articles, 14 of which you can access for free at:
http://www.jimmunol.org/content/185/10/5869.full#ref-list-1

**Why The *JI***? Submit online.

- **Rapid Reviews!** 30 days* from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

*average

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting

Merav Cohen,*1 Moshe Elkabets,†1 Michal Perlmutter,* Angel Porgador,† Elena Voronov,† Ron N. Apte,† and Rachel G. Lichtenstein* 

Sialylation of tumor cells is involved in various aspects of their malignancy (proliferation, motility, invasion, and metastasis); however, its effect on the process of immunoediting that affects tumor cell immunogenicity has not been studied. We have shown that in mice with impaired immunoediting, such as in IL-1α−/− and IFNγ−/− mice, 3-methylcholanthrene–induced fibrosarcoma cells are immunogenic and concomitantly bear low levels of surface sialylation, whereas tumor cells derived from wild type mice are nonimmunogenic and bear higher levels of surface sialylation. To study immune mechanisms whose interaction with tumor cells involves surface sialic acid residues, we used highly sialylated 3-methylcholanthrene–induced nonimmunogenic fibrosarcoma cell lines from wild type mice, which were treated with sialidase to mimic immunogenic tumor cell variants. In vivo and in vitro experiments revealed that desialylation of tumor cells reduced their growth and induced cytotoxicity by NK cells. Moreover, sialidase-treated tumor cells better activated NK cells for IFN-γ and IL-1β secretion. The NK2G2D-activating receptor on NK cells was shown to be involved in interactions with desialylated ligands on tumor cells, the nature of which is still not known. Thus, the degree of sialylation is impaired, such as in IFN-γ−/− and IL-1α−/− mice, the overt tumor consists of desialylated tumor cells that interact better with immunosurveillance cells.

Sialic acid, an acidic sugar at physiologic conditions that is found mainly at the outer ends of cell surface glycan chains, is elevated and frequently varied in glycan epitopes. In the malignant process, the presence of sialic acid is correlated with tumor cell proliferation, cell motility, invasion, metastasis, and poor prognosis (1–5). Studies addressing the effects of sialic acid on either tumor cell lipids or glycoproteins in modulating tumor-immune responses have shown that sialic acids can prevent cell–cell interactions, through nonspecific charge repulsion effects (6), participate in engagement of immune cell adhesion molecules such as the Ig-like lectin receptors (siglec)s (7, 8), and mask the underlying glycan structure, thus avoiding recognition by other lectins such as galectins and C-type lectins (9–11). Although effects of sialylation of selected tumor cells during tumor immunoediting and creating the immunogenic repertoire of malignant cells during tumorigenesis.

Several studies have experimentally proved the concept of immunoediting, in which immune responses of the host during tumorigenesis select tumor cell variants lacking stress ligands. Ags essential for immune recognition by immune effector cells, or tumor cells that can evade the immune system or subvert its function. When immunoediting is impaired, such as in IFN-γ−/− and IL-1α−/− mice, the overt tumor consists of desialylated tumor cells that interact better with immuno-surveillance cells.

The Journal of Immunology, 2010, 185: 5869–5878.

Abbreviations used in this paper: FSG, fish gelatin; i.f.p., intrafootpad; MCA, 3-methylcholanthrene; MFI, mean fluorescence intensity; SNA, sambucus nigra lectin; T-Ag, Galβ(1,3)GalNAcα-1; Tn-Ag, GalNAcα-1; WT, wild type.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10S16.00

*Department of Biotechnology Engineering, Faculty of Engineering; and †Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and National Institute of Biotechnology, Ben-Gurion University of the Negev, Beer-Sheva, Israel

1M.C. and M.E. contributed equally to this work.

Received for publication May 18, 2010. Accepted for publication September 17, 2010.

This work was supported by the Israel Glycobiology Center at Ben-Gurion University. R.G.L. is supported by the European Union Sixth Research Framework Programme (FP6). M.E. is supported by the International Sephardic Education Foundation and a Nehemia-Lev-Zion scholarship.

Address correspondence and reprint requests to Rachel G. Lichtenstein, Department of Biotechnology Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel. E-mail address: ruha@bgu.ac.il

The online version of this article contains supplemental material.

Abbreviations used in this paper: FSG, fish gelatin; i.f.p., intrafootpad; MCA, 3-methylcholanthrene; MFI, mean fluorescence intensity; SNA, sambucus nigra lectin; T-Ag, Galβ(1,3)GalNAcα-1; Tn-Ag, GalNAcα-1; WT, wild type.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10S16.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1001635
by serving as the first line of antitumor immune defense (21). The antitumor activity of NK cells is determined by a balance between stimulatory and inhibitory receptor signals, such as NKG2D and MHC class I molecules, respectively (22, 23). The abundant NKG2D ligands expressed on tumor cells better engage the activating NKG2D receptor, thus promoting NK-derived IFN-γ production. IFN-γ can activate various types of innate and adaptive immune mechanisms and enhance tumor cell lysis (24–26).

In this study, we have used an experimental model consisting of sialidase-treated cells derived from MCA-treated WT mice to assess the involvement of sialic acid residues in interactions of tumor cells with the host immune system. In a set of in vivo and in vitro experiments, we illustrate that the treated fibrosarcoma cells increased their immunogenic capacity and interactions with the host NK cells. Our in vivo experiments clearly show the involvement of NK cells in growth inhibition and lysis of sialylated tumor cells. Our studies revealed a correlation between sialic acid expression levels on tumor cells, NKG2D ligand receptor engagement, and NK cell cytotoxic activity. NKG2D was found to be crucial in low-sialylated tumor cell lysis. The therapeutic potential of the results is discussed below.

**Materials and Methods**

**Mice**

Female BALB/c mice (6–14 wk old) were purchased from Harlan Breeders (Livermore, CA), and IFN-γ knockout mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The generation of IL-10−/− mice was described previously (27). These mice were backcrossed with BALB/c mice for more than eight generations and were homozygous for the relevant mutation. The mice were bred and kept at the Animal Facilities of the Faculty of Health Sciences, Ben-Gurion University, under aseptic conditions. Mice were treated according to the National Institutes of Health Animal Care guidelines adopted by the Ben-Gurion University Committee for the Ethical Care and Use of Animals in Research.

**Cell lines and primary fibroblasts**

Fibrosarcoma cell lines were generated by injection of MCA (Sigma-Aldrich, St. Louis, MO), as previously described (28). Primary fibroblasts were produced from the dorsal skin of BALB/c and IL-10−/− mice, as described previously (29). The cells were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine, in a humidified 5% CO₂ atmosphere at 37°C. All medium ingredients were purchased from Biological Industries (Bet-Haemek, Israel).

**Sialidase treatment and kinetic analysis of sialic acid recovery**

For external reduction of terminal sialic acids, 6 × 10⁶ sialidase-treated cells with 10 mU sialidase A (ProZyme, San Leandro, CA). Treatment was performed in 100 μl sodium-phosphate buffer (pH 6) for 10, 30, 45, and 60 min at 37°C. For kinetic analysis of the recovery of sialic acid residues after 1 h of treatment, 5 × 10⁶ sialidase-treated cells were recultured in six-well plates in 2 ml medium. Cells were then harvested by trypsin-EDTA treatment at different points over 48 h. After multiple washes with PBS, the cells were fluorescently labeled with sambucus nigra lectin (2.5 ng per sample) in PBS containing 0.2% FSG and inspected with an inverted microscope equipped with an Olympus IX81 camera, using appropriate fluorescent filters (Olympus, Center Valley, PA).

**Invasiveness of 3-MCA-induced cell lines**

For determining tumorigenicity patterns of sialidase-treated and untreated MCA-induced fibrosarcoma cells, 1 × 10⁵ cells were suspended in 200 μl PBS and injected i.v. into the tail vein of mice. Two weeks later, mice were sacrificed and their lungs were weighed and photographed with a digital camera. Mouse survival was determined daily during the 40 d after i.v. injection.

**Spleen cell isolation and NK cell enrichment**

Spleen cells derived from mice were cultured in 24-well plates at a concentration of 1 × 10⁶ cells per well. Splenic NK cell were enriched using a negative selection kit, according to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). NK cell enrichment was verified by FACS analysis. Approximately 75–90% of the recovered cells were CD3⁺ CD5⁺ CD122⁺.

**Coculturing of tumors with immune cells and NKG2D ligand blocking**

MCA-induced fibrosarcoma cells treated with mitomycin-C (Sigma-Aldrich; 100 μg/10⁶ cells treated for 1 h at 37°C) were added to naive spleen or enriched NK cells, as described previously (24). Cocultures were incubated in RPMI 1640 medium (Invitrogen) supplemented with 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 100 ng/ml IL-2. Coculture supernatants were collected 24 h after seeding, and cytokine amounts in the culture supernatants were measured by ELISA. To quantify secreted IFN-γ in cocultures with a blocked NKG2D receptor, 1 × 10⁶ enriched NK cells were preblocked with 0.5 μg anti-NKG2D/CD134 Abs (eBioscience, San Diego, CA) in a volume of 100 μl for 30 min at 4°C. The treated NK cells were cocultured with sialidase-treated or untreated cells after supernatant collection and cytokine assessment by ELISA.

**Intracellular staining**

For intracellular IFN-γ detection, cocultures were supplemented with 100 ng/ml IL-12, followed by Golgi-stop treatment (BD Biosciences, San Jose, CA) using a diluted stock solution of 1:1000 12 h later, and stained using a Cytometric Kit according to the manufacturer’s instructions (BD Pharmingen, San Diego, CA). The cells were finally stained with NK cell markers and anti–IFN-γ Abs and subsequently quantified by FACS analysis.

**NKG2D-Ig ligand binding**

For detection of NKG2D ligands by flow cytometry, cell lines were stained with a mNKG2D-fusion protein (mNKG2D-FP) (31). For kinetic measurements of NKG2D ligand–receptor interactions, 6 × 10⁶ untreated fibrosarcoma cells were preincubated with 10 mU sialidase every 10 min for 1 h. The treated cells were washed with PBS and then incubated with mNKG2D receptor-fusion protein (mNKG2D), as described previously (30).

**In vivo depletion of lymphoid cell subpopulations**

In vivo depletion of CD4⁺ and CD8⁺ T cells was achieved via multiple i.p. injections of ascitic fluids containing the relevant monoclonal Abs—GK1.5 and YTS-169, respectively. Injection of Abs was performed on days

**Fluorescence microscopy**

Cells (1 × 10⁵) were fixed in 4% formaldehyde in PBS for 15 min at room temperature, washed with PBS, and blocked with 1% fish gelatin (FSG) in PBS-Tween solution for an additional 30 min. Next, FITC-labeled SNA lectin (2.5 ng per sample) in PBS containing 0.2% FSG was added for 1 h at room temperature and then washed three times. Fluorescent staining of actin filaments was observed following labeling by (1:500) Oregon Green 488 phallolidin (Invitrogen) in PBS containing 0.2% FSG. For nuclear staining, (1:1000) Hoechst dye (Invitrogen) in PBS containing 0.2% FSG was added. Finally, all cover slips were placed on slides containing 50% glycerol and inspected with an inverted microscope equipped with an Olympus IX81 camera, using appropriate fluorescent filters (Olympus, Center Valley, PA).
To detect surface α2-6 sialic acids on primary and tumor cells, skin fibroblasts and MCA-induced tumor cell lines were stained with FITC-labeled SNA lectin, as described previously (25). For detection of MHC class I and NKGD2 ligands, the cell lines were harvested and blocked with PBS plus 0.5% FBS and purified anti-CDD16/CDD32 Abs (Biolegend, San Diego, CA). Subsequently, the cells were stained with MHC class I-FITC–conjugated mouse anti–H-2Kk mAbs (clone SF1-1.1; BD Pharmingen) and mNKGD2-FP. Biotinylated donkey anti-human IgG antiserum (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as a second-step reagent, followed by staining with PE-conjugated streptavidin (Jackson ImmunoResearch Laboratories).

Isolated spleen cells from BALB/c mice were stained for cell subsets by APC-PE–labeled anti-CD49b (clone DX5; Biolegend), anti-mouse CD122–APC-PE (BD Biosciences), FITC–anti-mouse CD3ε (Biolegend), and ALEXA647–anti-mouse NKP46 (eBioscience) Abs.

**Frozen and paraffin section analysis**

Tumors were removed from the footpads or lungs of mice injected with sialidase-treated or untreated tumor cells. For paraffin sections, the tumors were immediately fixed and stained with H&E using an established protocol (27). For frozen sections, tumors were fixed and stained as described previously (32). Paraffin or frozen stained sections were viewed with light or confocal microscopes at ×20 and ×40 magnification, respectively.

**Measurement of secreted cytokines**

Murine IFN-γ, TNF-α, IL-2, IL-6, and IL-12 levels were measured using a commercial ELISA kit (BD Pharmingen), according to the manufacturer’s instructions and as described previously (33).

**Cytolytic assay**

For in vitro and in vivo NK cell cytolytic activity assays, 200 μg of poly(I):poly(C) (Sigma-Aldrich) were injected into naive mice, and spleen cells were removed 18 h later (34). The cytolytic activity was evaluated in cocultures of target cells with the treated spleen cells in a 4-h CFSE/7-AAD flow cytometry assay as described (35). For in vivo NK cell-killing assays (34), sialidase-treated cells were labeled with the fluorescent dye Vybrant Dil (Invitrogen), and untreated cells were labeled with the fluorescent dye Vybrant DiD (Invitrogen). Cells were mixed at a density of 2 × 10^6 cells of each population per milliliter of PBS, and 200 μl of the mixture was injected into the tail vein. Lungs were collected after the injections or 5 h later, single-cell suspensions were obtained with cell strainers, and fluorescence was analyzed by flow cytometry. The ratio of treated target cells to untreated cells was calculated. For in vivo NK cell killing after NKGD2 blocking, mice were injected i.p. with 200 μg anti-NKGD2/CD134 Abs per mouse, 24 h before injection of sialidase-treated and untreated tumor cells.

**Cell conjugation and confocal analysis**

To evaluate the number of immune synapses formed by NK and target cells, poly(I):poly(C) activated NK cells were isolated from naive mice and conjugated to sialidase-treated or untreated fibrosarcoma cells at a ratio of 2:1 on poly-l-lysine–coated glass slide chambers (Sigma-Aldrich). Adherent cells were fixed, permeabilized, and washed and using the Cytofix/Cytoperm kit (BD Biosciences). Staining NK and tumor cell conjugates with anti-mouse CD11a Abs (clone M17/4; Biolegend) was followed by staining with Alexa Fluor 635–conjugated anti-rat IgG (Invitrogen) for LFA-1 detection. To detect F-actin, cells were stained with Oregon green 488 phalloidin (Invitrogen). VECTASHELD Mounting Medium (Vector Laboratories) with DAPI was subsequently added to stain nuclei and preserve fluorescent intensity. The cell conjugates were viewed in a Zeiss Laser Scanning Confocal Microscope (Goettingen, Germany). Each conjugate was scored for polarization of the activating synapse markers LFA-1 and F-actin, as described previously (36). Synapse formation percentages were calculated by dividing the number of conjugates showing polarization of activating synapse markers to the total number of conjugates.

**Statistical analysis**

Each experiment was repeated at least three times with similar response patterns. In experiments on the invasiveness of MCA-induced fibrosarcoma cell lines, experimental groups consisted of 5–10 mice. The data shown correspond to pooled or single representative experiments, as indicated, and are expressed as mean ± SD. Significant differences in results were determined using the two-sided Student t test, with p < 0.05 being considered significant.

**Results**

**Surface sialylation levels of MCA fibrosarcomas derived from immunodeficient or BALB/c mice are slowly recovered after sialidase treatment**

We first documented the natural level of sialic acids in MCA fibrosarcomas derived from WT mice. The sialic acid levels were compared with those inspected in immunogenic fibrosarcoma cell lines originating from IL-1α−/− mice (19), as well as in primary fibroblasts, by fluorescence microscopy and flow cytometry using FITC-tagged SNA, which is able to bind α2-6 sialic acid. Whereas primary fibroblasts derived from WT and IL-1α−/− mice showed similar staining with SNA (Fig. 1A), MCA-induced fibrosarcoma cell lines derived from IL-1α−/− mice exhibited lower staining and binding with SNA, as compared with fibrosarcoma cell lines derived from WT mice (Fig. 1A). These results coincide with flow cytometry evaluations of sialic acid levels in additional MCA-induced fibrosarcoma cell lines originated from IFN-γ−/− mice in our laboratory (Fig. 1B). Mice lacking IFN-γ have been shown to bear increased susceptibility to MCA-induced sarcoma (20). As such, sarcoma immunogenicity in the second recipients was confirmed in our IFN-γ−/− cell lines. As expected, IFN-γ−/− cells injected i.p. developed tumors at a lower rate than did WT fibrosarcomas (Fig. 1B). Collectively, these results indicate that sialic acid surface expression is elevated during carcinogenesis and is associated with tumor immunoediting.

Fibrosarcoma cell lines derived from WT mice were treated with sialidase A, which cleaves nonreducing terminal sialic acid in α2, α3, α6, α8, or v9 linkages and which are stained by SNA (Supplemental Fig. 1A). The renewal of sialic acid levels to the original status was examined in sialidase-treated WT and IL-1α−/− fibrosarcoma cell lines. According to our previous study, MCA-induced fibrosarcoma cell lines derived from IL-1α−/− mice express lower amounts of α2-6 sialyltransferase (ST6GalI) compared with fibrosarcoma cells derived from naive BALB/c mice (19). Therefore, the recovery of sialic acids on IL-1α−/− tumor cells was also 50% lower than sialic acid recovery on fibrosarcoma cell lines derived from BALB/c mice at the same time (Supplemental Fig. 1B). Complete recovery of sialic acid levels was obtained after ~48 h, a period that allows in vivo examination of the immune response of the sialidase-treated tumor cells.

To verify that cellular competency was not impaired by the sialidase treatment, the rates of proliferation, the ratio of apoptosis, and the ability of the cells to form colonies on soft agar were assessed. No significant differences in proliferative ability, colony formation, or apoptotic ratios were observed between the sialidase-treated and untreated cells. These results indicate that sialidase-treated cells can be used as a model for studying the role of tumor cell sialylation in antitumor immunity in vivo (Fig. 1C).

**Host response to sialidase-treated tumor cells results in tumor growth inhibition**

We next studied the in vivo contribution of desialylated fibrosarcoma cells to tumor progression. Injection of sialidase-treated tumor cells into the footpads of syngenic mice resulted in an
inhibition of tumor growth that lasted ∼30–40 d after tumor cell injection, as compared with the rapid tumor growth rate observed with untreated cells (Fig. 2A). Similar injection of treated cells 0–60 min after sequential sialidase treatments resulted in a linear gradient of tumor growth inhibition (Supplemental Fig. 2A). In addition, i.v. injection of sialidase-treated cells into mice resulted in 100% survival, compared with the earlier death of mice injected with untreated cells (Fig. 2B). Lung analysis performed 2 wk after untreated cell injection showed significantly high metastasis formation, as indicated by lung weights in mice injected with untreated cells, relative to lungs from mice injected with treated cells (Fig. 2C). Next, sialidase-treated and untreated tumor cells were injected i.f.p. and i.v. into immunocompromised, sublethally irradiated mice. The sialidase-treated and untreated tumor cells induced the formation of solid tumors, leading to similar kinetics of sialidase-treated tumor growth inhibition following i.f.p. injection, as observed in intact mice. By contrast, NK cell depletion had the most significant effects on the growth of sialidase-treated tumor cells, as compared with growth in intact mice (Fig. 3A). Lung weights were significantly elevated in NK-depleted mice that were injected i.v. with sialidase-treated cells, as compared with lung weights measured in CD4+-depleted, CD8+-depleted, or WT mice injected with treated cells (Fig. 3B).

Further evidence pointing to the NK cell involvement in tumor inhibition of sialidase-treated cells was observed by immunohistochemical examination of frozen sections. Analysis of the i.f.p. injection site revealed significant accumulation and migration of infiltrate cells within 2 d after sialidase-treated cell injection (Fig. 3C). Finally, the number of synapses was evaluated by conjugating activated NK cells to sialidase-treated or untreated cells. Immune synapses were quantified by determining the polarization of LFA-1 and F-actin at the interface between the effector and target cells. Anti-CD11a (LFA-1) Abs stained integrin molecules that participate
in the adhesion and stimulation of NK cells and their target cells. F-actin staining showed tight collars at the contact site owing to the accumulation of actin during formation of conjugates (Fig. 3D). There were 3-fold more immune synapses between NK cells and sialidase-treated cells compared with untreated cells. In some cases, a single NK cell was found to form simultaneous immune synapses with more than one sialidase-treated tumor cell. In contrast, fewer synapses were formed by highly sialylated tumor cells and NK cells. These data show the contribution of NK cells to sialidase-treated tumor cell inhibition in vivo and show the cytotoxic interactions between NK cells and sialidase-treated tumor cells in vitro.

**Reduction of sialic acid levels triggers IFNγ secretion and NK cell cytotoxicity**

To further investigate the nature of the immune response against sialidase-treated cells, immune-secreted cytokines were assessed in vitro. Coculturing of sialidase-treated tumor cells with naive...
spleen cells for 24 h resulted in an induction of IFN-γ secretion to a level 2-fold higher than that observed in response to untreated cells (Fig. 4A). Coculturing of tumor cells treated with sialidase for 30, 45, and 60 min inversely correlated with IFN-γ production (Fig. 4B). This finding was due to a 50%, 60%, and 75% gradient of sialic acids generated on the tumor cells. NK cell depletion reduced IFN-γ concentration by 50% in cocultures of spleen cells with sialidase-treated tumor cells, as compared with similar incubation with intact spleen cells (Fig. 4C). By contrast, similar IFN-γ concentrations were observed in untreated tumor cells cocultured with either NK-depleted or intact spleen cells, indicating that the NK cells are the major source of IFN-γ production when interacting with sialidase-treated cells. Likewise, TNF-α, IL-2, IL-4, IL-6, and IL-12 were not differentially secreted in response to coculturing with sialidase-treated or untreated tumor cells (data not shown). In addition, comparison of IFN-γ levels secreted by cocultures of the immunogenic IL-1α−/− tumor cells with naive spleen cells revealed increased IFN-γ secretion to a level 10- or 5-fold higher than observed in response to untreated cells (Supplemental Fig. 3) or treated cells, respectively, as shown in Fig. 4A. Most likely, IL-1α−/− tumor cells trigger more than one immune cell populations to produce IFN-γ, whereas sialidase-treated cells mainly trigger the NK cell population.

To confirm that IFN-γ is secreted by NK cells, intracellular staining of the various cocultures was performed, whereas naive spleen cells were stained for DX5+ and CD3+ to confirm expression of the NK cell marker NKp46 (Supplemental Fig. 4). As shown in Fig. 4D, IFN-γ accumulated in DX5+CD3+ cells from cultures containing sialidase-treated cells to twice the level seen in cultures containing untreated cells. Moreover, in cocultures of freshly isolated NK cells and sialidase-treated cells, IFN-γ accumulation increased by more than 2-fold, relative to levels in cocultures of freshly isolated NK and untreated cells (Fig. 4E).

Finally, the role of NK cells in the lysis of sialidase-treated cells was illustrated in vitro by addressing cocultures containing poly(I):poly(C) pretreated naive spleen cells and by in vivo i.v. injections of a labeled sialidase-treated and untreated cell mixture. The coculturing results revealed 32% specific lysis of sialidase-treated cells, relative to the low percentages observed in untreated cells (Fig. 4F). In vivo lysis decreased from an initial ratio of 1.0 between treated to untreated cells after injection to a ratio of 0.71 after 1 h and to a ratio of 0.23 5 h later, indicating a rapid lysis of sialidase-treated cells compared with untreated cell lysis (Fig. 4G). These results reveal that poorly sialylated tumor cells are more susceptible to NK cells than are highly sialylated tumor cells.

Sialylation is involved in the binding of NKG2D ligands and affects subsequent IFN-γ secretion and NK cell cytotoxicity

In certain conditions, stress-induced ligands, such as NKG2D ligands, induce NK cell activation and IFN-γ secretion. Because the involvement of tumor sialylation in NKG2D engagement and IFNγ secretion had not been characterized, we initially
assessed NKG2D ligand binding to an mNKG2D fusion protein. The dependency of NKG2D engagement on sialic acid expression was illustrated by kinetic experiments. MCA-induced fibrosarcoma cells derived from WT mice were treated with sialidase for 1 h. Every 10 min during the treatment, cells were assessed for sialic acid and MHC class I levels, using SNA lectin and anti-H-2K^d Abs, respectively. Binding of the mNKG2D fusion protein increased with a decrease in SNA binding, whereas MHC class I binding to anti-H-2K^d Abs did not change during the sialidase treatment (Fig. 5A). These findings show the effect of the sialylation level on the ability of tumor NKG2D ligands to be engaged by the NKG2D receptor (Fig. 5B).

Because the increase in binding capacity of NKG2D ligands is related to the ability of NK cells to produce IFN-γ or cytotoxic activity, we were interested in assessing these phenomena as a function of different levels of tumor sialylation. Accordingly, the NKG2D receptor was blocked by pretreatment of freshly isolated NK cells with anti-NKG2d/CD134 Abs, followed by coculturing with tumor cells. Cocultures of sialidase-treated tumor cells with the blocked NK cells revealed reduced IFN-γ production (by 50%), whereas a 20% reduction was observed in cocultures with untreated tumor cells, compared with the IFN-γ production attained without blocking (Fig. 5C). Lysis of sialidase-treated cells cocultured with poly(I):poly(C)-induced spleen cells was reduced by 50–80% after NKG2D blocking; however, cocultures of untreated cells grown in the same conditions showed less significant lysis reduction after blocking (Fig. 5D). Finally, the involvement of NKG2D in lysis of sialidase-treated cells was assessed in vivo by i.v. injection of the cells into mice pretreated with 200 μg anti-NKG2d mAbs. Lysis of sialidase-treated cells was significantly reduced in NKG2D-treated mice, as compared with their lysis in naive mice (Fig. 5E). Thus, IFN-γ production and cell lysis are regulated by the accessibility of NKG2D ligands for binding to the NKG2D receptor. Accordingly, reduced sialic acid levels promote IFN-γ production and cell lysis by encouraging the binding of NKG2D to the receptor on NK cells.

Discussion
This study demonstrates that surface sialylation is an important element of the MCA-induced cancer-immunoediting process. Thus, the degree of sialylation of surface molecules is one of the parameters selected during immunoediting of the tumor cell repertoire during tumorigenesis, which shapes the intrinsic immunogenicity of the malignant cells and patterns of their interactions with the host immune system. Specifically, low levels of sialic acid on tumor cells in mice with impaired immunoediting are associated with increased interactions of the malignant cells with effector cells of the host immune system, leading to malignant cell rejection.
FIGURE 5. Sialylation is involved in the binding of NKG2D ligands and affects subsequent IFN-γ secretion and NK cell cytotoxicity. A. Four to five different MCA fibrosarcoma cell lines derived from WT mice were treated with sialidase, and binding of mNKG2D or mNCR1 fusion proteins was assessed. MCA fibrosarcoma cells derived from WT mice were treated with sialidase at 10 min intervals for 1 h to generate tumor cells bearing decreasing sialic acid levels on their surface. B. By using SNA lectin, anti–H-2Kd Abs, or fmNKG2D, the sialic acid levels (○), MHC class I presence (▲), or NKG2D ligand levels (□) were measured, respectively, and analyzed by flow cytometry. The binding values are presented as percentages, relative to the binding observed before sialidase treatment. C. Sialidase-treated or untreated cells were cocultured with activated NK cells or NKG2D-blocked NK cells, at a ratio of 1:1. NKG2D receptor blocking of the activated NK cells was observed by anti–NKG2D-CD134 Ab treatment; 24 h after coculturing these cells, IFN-γ secretion levels were measured in the supernatant by ELISA. D. Poly(T):poly(C) activated naive spleen cells labeled with CFSE were cocultured with sialidase-treated or untreated cells in the presence of anti–NKG2D-CD134 Abs (○, □) or without these Abs (△, ▽) at different target:effector ratios. D. After 5 h incubation at 37°C, cells were stained with 7-AAD, and specific lysis was calculated relative to the spontaneous lysis. E. Vybrant Dil-labeled sialidase-treated and Vybrant DiD-labeled untreated cells (2 × 10⁶) were mixed and injected into the tail veins of naive mice or mice preinjected with 200 µg anti–NKG2D-CD34 Abs. Lungs were harvested and cells were quantified 0 and 5 h after injection using flow cytometry. The ratio of treated target cells to untreated cells was calculated. Data represent the mean ± SD of duplicate or triplicate measurements from duplicate or triplicate independent experiments. **p < 0.01; *p < 0.05, versus the appropriate controls in each panel.

in intact mice. In mice with an intact immune system, the malignant cells that arise during MCA-induced carcinogenesis are enriched with surface sialic acid residues and are not eradicated by the immune responses. These observations were obtained when using MCA fibrosarcoma cell lines derived from IL-1α−/− mice (18, 19), in which impaired immunooediting has been observed. In the case of MCA-induced fibrosarcoma cells from IL-1α−/− mice, we detected lower expression of α2-6 sialyltransferase, compared with MCA-induced lines derived from WT mice, which corroborates the results of Avidan et al. (19). Our data suggest that sialylation of the tumor cell surface or sialylation of specific moieties determines the differential ability to stimulate different immune responses. It has to be elucidated whether these observations also hold for immunooediting of epithelial tumors. Experimental approaches to assess the creation of the immunogenic repertoire during epithelial carcinogenesis are rare and complicated and have not been approached appropriately.

The less sialylated membrane-bound glycoconjugates were mimicked in this study to assess their interaction with the host immune system, using sialidase-treated nonimmunogenic cells derived from MCA-induced WT mice. The major immune cell type, which was shown to interact best with sialidase-treated tumor cells, is the NK cell. Alterations in cancer cell sialylation have been correlated previously with changes in the activity of one or more of 20 different sialyltransferases (37) in malignant cells (4). Alterations in sialylation levels of malignant cells have usually been associated with changes in invasiveness and metastasis patterns, yet seldom related to the immunogenicity of the cells or their interaction patterns with immune effector cells. Concerning sialylated tumor cell interactions with immune effector cells, it was shown, for example, that sialylated GM2 gangliosides on YAC-1 lymphoma cells inhibit in vitro interactions with cytotoxic NK cells (38). The oversialylated T- and Tn-Ags of MUC1 in breast carcinoma cells simultaneously increased IL-10 and reduced IL-12 production by dendritic cells (39). The GD3 ganglioside on tumor cells, when enriched with disialic acids, inhibits cytotoxicity of NK cells via siglec-7 (40). High levels of gangliosides secreted by tumor cells inhibit the expression of costimulatory molecules on dendritic cells, subsequently reducing APC-dependent T cell proliferation (41). All these reports show that sialylated molecules expressed on or secreted by the malignant cells induce immune evasion by the malignant cells and their subsequent progression. Accordingly, reduction of tumor cell sialylation levels should lead to better antitumor immune responses, as observed in this study.

In this study, we have also shown the role of sialic acids on tumor cell killing activity, contact with NK cells, and IFN-γ secretion by NK cells. Thus, depletion experiments confirmed the
involvement of NK cell-mediated in vivo growth inhibition of desialylated tumors. The increase in the number of immune synapses formed between NK cells and sialidase-treated tumor cells demonstrated that their interactions are essential for lysis of malignant cells by NK cells. In addition, NK cells were shown to represent the major population that secretes augmented amounts of IFN-γ after interacting with sialidase-treated tumor cells in vitro. NK cell-derived IFN-γ may be involved in modulating innate and adaptive immune responses (42). For example, priming of Th1-biased T cell responses promotes the development of an antitumor CD8+ T cell response (43) or can activate macrophages and possibly other effector cells, leading to enhanced tumoricidal activity (44). Depletion of CD4+ or CD8+ T cells did not shift growth patterns of sialidase-treated tumor cells, whereas NK cell depletion induced progressive growth. This finding implies that NK cells rather than adaptive immune cells possibly control the initial phase of tumor growth.

NKG2D has been shown to play a prominent role in the antitumor immune response (45) by coupling the NKG2D receptor to its ligands on tumor cells, which triggers NK cell cytolytic activity and IFN-γ secretion (46, 47). Our results show enhancement of NKG2D receptor–ligand interactions, but no alteration in the levels of MHC class I expression, upon removing sialic acids. NKG2D receptor–ligand interactions in the sialidase-treated tumor cells were correlated to enhanced secretion of IFN-γ and in vitro or in vivo killing capacity. Moreover, blocking NKG2D prevented the interactions with the sialidase-treated cells, thus decreasing the lysis of these tumor cells by the cytotoxic NK cells. We hypothesize that tumor cell sialylation prevents the interactions of NKG2D receptor ligands through nonspecific charge repulsion of sialic acid residues near the NKG2D ligands (48). Another possible option for preventing ligand–receptor interactions is sialylation of NKG2D ligands (49), which have several potential glycosylation sites on their backbones (accession nos. O08602, O08603, and O08604 SwissProt database: http://www.expasy.org/sprot/). However, O’Callaghan et al. (50) showed that NKG2D glycosylation is not necessary for the NKG2D–REA1 and NKG2D–H60 interactions. Further work is needed to demonstrate how sialylation affects NKG2D ligand function regarding NK cell cytotoxicity and, if so, which NKG2D ligand is affected by sialylation and by which mechanism.

In conclusion, a high degree of tumor cell sialylation is a factor that was selected in the process of immunoeediting during carcinogenesis. Although the direct interactions of sialic acid residues with lectin receptors, such as siglecs on NK cells, can be a negative regulator of cytolytic responses, we focused on signals activating the immune system by low sialylated tumor cells. By reducing surface sialylation, we generated more immunogenic tumor cell variants, which activated innate immune cells. By reducing surface sialylation, we generated more immunogenic tumor cell variants, which activated innate immune cells. By reducing surface sialylation, we generated more immunogenic tumor cell variants, which activated innate immune cells.

Acknowledgments

We thank Rosalyn M. White and Rona Baron from the Microbiology and Immunology Department of Ben-Gurion University for technical assistance.

Disclosures

The authors have no financial conflicts of interest.

References


